ResMed Inc. reported remarkable Q4 CY2025 results, achieving $1.42 billion in revenue, an 11% year-over-year increase that exceeds expectations. The company's non-GAAP profit of $2.81 per share also surpassed analyst predictions, while gross margin expanded by 310 basis points. Alongside these financial achievements, ResMed is ramping up share repurchases to over $600 million for FY2026 and enhancing its product offerings, positioning itself for significant growth in the competitive healthcare market.
“ResMed · has an estimated long-term growth rate of · 13.7% · true”
“Top gainers in premarket trading included · companies · ResMed Inc. · +3.95%”
“ResMed · has an estimated long-term growth rate of · 13.7% · true”
“ResMed (NYSE:RMD) · develops · medical devices and software solutions · for sleep apnea, COPD, and other respiratory disorders”
“Dr. Peter Farrell · is the founder of · ResMed · true”
“ResMed · reported · Q4 CY2025 results · beating Wall Street’s revenue expectations, with sales up 11% year on year to $1.42 billion”
“ResMed · reported · non-GAAP profit · $2.81 per share”
“ResMed · achieved · operating margin · 34.6%”
“ResMed · recorded · adjusted EBITDA · $570.5 million”
“ResMed · has · market capitalization · $37.52 billion”
“ResMed Inc · reported · headline revenue growth · 11%”
“ResMed Inc · achieved · growth in GAAP EPS · 16%”
